A 52-year-old woman had been receiving golimumab, another TNF-α inhibitor, for AS associated with UC since 2019. Golimumab is a human monoclonal antibody that also binds to TNF-α, thereby blocking its pro-inflammatory effects. Despite its use, the patient's condition did not improve.

Her medical history included hepatitis B and thyroid nodules, for which she was not receiving any treatment.

In September 2023, due to therapeutic failure, golimumab was discontinued and replaced with adalimumab.

On